Company attributes
Amaksa is a pharmaceutical company specializing in a wide range of prescription and over-the-counter drugs for the treatment of oncology, hematology, and neonatology.
History of the company
Amaxa, headquartered in the UK, was founded over ten years ago.
Since 2012, the Ukrainian representative office of Amaks Ukraine has been operating.
Since 2012, Amaxa has partnered with Texas-based Caris Life Sciences® to provide Ukrainian patients with access to Caris® Molecular Intelligence.
In April 2015, the US Food and Drug Administration's (FDA) Committee on Cardiovascular and Renal Medicines approved Kengrexal (cangrelor).
In 2018, new angiography centers were opened in 11 regions of Ukraine.
At the beginning of 2020, Amaxa began supplying Kengrexal (cangrelor) in Ukraine. It is an innovative short-acting injectable antiplatelet agent for periprocedural prevention of thrombotic events in patients undergoing percutaneous intervention (PCI).
